Cannabis in Adults with Cancer
Key Points
Key Points
- Cannabis and/or cannabinoid access and use by adults with cancer has outpaced the science supporting their clinical use.
- This guideline provides strategies for open, nonjudgmental communication between adults with cancer and clinicians about the use of cannabis and cannabinoids.
- Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial.
- Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting (CINV) when added to guideline-concordant antiemetic regimens.
- Whether cannabis and/or cannabinoids can improve other supportive care outcomes remains uncertain.
Treatment
Treatme...
...l Communication and Education...
...ndation 1.1Health systems and clinici...
...mendation 1.2Given the high prevalence of can...
...ndation 1.3When adults with cancer use ca...
...er Treatment...
...dation 2.1Clinicians should recommend against use...
...ion 2.2Clinicians should recommend...
...atment-related Toxicity, Symptoms, an...
...ommendation 3.1
...nabinol and nabilone] (EB, , M, Weak)3...
...THC:CBD extract] (EB, , L, Weak)3499376...
...ion 3.2Outside of a clinical trial, clinician...
...n 3.3Evidence remains insufficient to...
...e 1. Taking an In-depth History of Canna...
...Summary of Recommendations Pertaining t...
...Safety AwarenessHaving trouble viewing...
...gure 1. Endocannabinoid Sys...
...ves that cancer clinical trials are vital to info...